Human atrial natriuretic peptide attenuates renal ischemia-reperfusion injury.
BACKGROUND
Acute kidney injury (AKI) is common in the intensive care unit, and one of its primary causes is renal ischemia-reperfusion (I/R) injury. Human atrial natriuretic peptide (hANP) exerts various pharmacologic effects, including renal protection. In the present study, we evaluated the renal protective effect of hANP in a rat model of renal I/R.


METHODS
Male Wistar rats were divided into three groups that received the following treatments: induction of renal I/R (I/R group); continuous intravenous injection of hANP followed 30 min later by induction of renal I/R (hANP+I/R group); and sham treatment (control group). Rats were sacrificed after 60 min of ischemia and 24 h of reperfusion or sham treatment. To evaluate the renal protective effects if hANP, serum blood urea nitrogen (BUN) and creatinine (Cre) concentrations were determined, kidneys were histologically assessed, and serum biomarkers of oxidative stress were evaluated. In addition, antimycin A (AMA)-stimulated RAW264.7 cells were treated with hANP to assess its antioxidant effects.


RESULTS
Serum BUN and Cre levels were elevated in the I/R group; however, these increases were significantly inhibited in the hANP + I/R group. Similarly, kidney tissue damage observed in the I/R group was attenuated in the hANP + I/R group. In vitro, AMA-stimulated cells treated with hANP showed reduced reactive oxygen species activity compared to cells treated with AMA alone.


CONCLUSIONS
Our findings indicate that hANP may be effective in the treatment of various types of I/R injuries.
Department of Anesthesiology and Intensive Care Medicine, Oita University Faculty of Medicine, Yufu City, Oita, Japan.
Hironori
H
Koga
Satoshi
S
Hagiwara
Junya
J
Kusaka
Shigekiyo
S
Matsumoto
Taichi
T
Nishida
Isao
I
Yokoi
Takayuki
T
Noguchi
D000080242:8-Hydroxy-2'-Deoxyguanosine; D058186:Acute Kidney Injury / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000737:chemistry / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D002460:Cell Line; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000097:blood; D006801:Humans; D017665:Hydroxyl Radical / Q000737:chemistry; D007668:Kidney / Q000473:pathology; D008297:Male; D018384:Oxidative Stress; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors; D015427:Reperfusion Injury / Q000097:blood / Q000473:pathology / Q000517:prevention & control*
D015415:Biomarkers; D017382:Reactive Oxygen Species; D017665:Hydroxyl Radical; D009320:Atrial Natriuretic Factor; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine